Asymptomatic peripheral arterial disease: Is pharmacological prevention of cardiovascular risk cost-effective?

European Journal of Preventive Cardiology

Volumn 18, Issue 2, 2011, Pages 254-261

  Sigvant, B ^a,b   Henriksson, M ^c   Lundin, F ^d   Wahlberg, E ^a,e  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Karstad Hospital   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

^d Karlstad Hospital   (Sweden)

^e LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cost benefit analysis; peripheral vascular disease; pharmacological prevention

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; ASYMPTOMATIC PERIPHERAL ARTERIAL DISEASE; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; ENZYME INHIBITION; HEALTH CARE COST; HEART RATE; HUMAN; LOW DRUG DOSE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASYMPTOMATIC DISEASES; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG COSTS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MODELS, ECONOMIC; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; PREVENTIVE HEALTH SERVICES; QUALITY-ADJUSTED LIFE YEARS; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SWEDEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 79959229589     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/1741826710389368     Document Type: Article

References (46)

1. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381–386.
2. Newman AB, Shemanski L, Manolio TA, Cushman M, Mittelmark M, Polak JF, et al. Ankle-arm index as a predictor of cardiovascular disease and mortality. Arterioscler Thromb Vasc Biol 1999; 19: 538–545.
3. Sigvant B, Wiberg-Hedman K, Bergqvist D, Rolandsson O, Andersson B, Persson E, et al. A population-based study of peripheral arterial disease prevalence. J Vasc Surg 2007; 45: 1185–1191.
4. Heald CL, Fowkes FG, Murray GD, Price JF. Risk of mortality and cardiovascular disease associated with the ankle-brachial index. Atherosclerosis 2006; 189: 61–69.
5. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease. Circulation 2006; 113: 509–510.
6. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33(Suppl 1): S1–75.
7. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Eur J Cardiovasc Prev Rehabil 2007; 14(Suppl 2): S1–113.
8. Sigvant B, Wiberg-Hedman K, Bergqvist D, Rolandsson O, Wahlberg E. Risk factor profiles and use of cardiovascular drug prevention in women and men with peripheral arterial disease. Eur J Cardiovasc Prev Rehabil 2009; 16: 39–46.
9. Bashir R, Cooper CJ. Evaluation and medical treatment of peripheral arterial disease. Curr Opin Cardiol 2003; 18: 436–443.
10. Belch J, Stansby G. Peripheral arterial disease: still on the periphery? BMJ 2006; 332: 1213–1213.
11. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States. Circulation 2004; 110: 738–743.
12. Criqui MH, Ninomiya JK, Wingard DL, Ji M, Fronek A. Progression of peripheral arterial disease predicts cardiovascular disease morbidity and mortality. J Am Coll Cardiol 2008; 52: 1736–1742.
13. Bendermacher BL, Teijink JA, Willigendael EM, Bartelink ML, Buller HR, Peters RJ, et al. Symptomatic peripheral arterial disease: the value of a validated questionnaire and a clinical decision rule. Br J Gen Pract 2006; 56: 932–937.
14. Dental and Pharmaceutical Benefits Agency, TLV. 2009. Pharmaceutical pricing and reimbursement information, http://www.lakemedelsverket.se/english/2009 consulted June 2007.
15. Briggs AH, Ades AE, Price MJ. Probabilistic sensitivity analysis for decision trees with multiple branches. Med Decis Making 2003; 23: 341–350.
16. Hooi JD, Kester AD, Stoffers HE, Rinkens PE, Knottnerus JA, van Ree JW. Asymptomatic peripheral arterial occlusive disease predicted cardiovascular morbidity and mortality. J Clin Epidemiol 2004; 57: 294–300.
17. Riks-Stroke; Swedish stroke register 2009, http://www.riks-stroke.org yearly national report.
18. The register of information and knowledge about Swedish heart intensive care admissions RIKS-HIA 2009, http://www.ucr.uu.se/rikshiaint/ yearly national report.
19. Council for official statistics in Sweden, 2006, http://www.scb.se.
20. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events CAPRIE. Lancet 1996; 348: 1329–39.
21. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22.
22. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial. BMJ 2008; 337: 1840–1850.
23. Catalano M, Born G, Peto R. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease. J Intern Med 2007; 261: 276–284.
24. Ostergren J, Sleight P, Dagenais G, Danisa K, Bosch J, Qilong Y, et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004; 25: 17–24.
25. Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J 2009; 30: 192–201.
26. Resnick HE, Lindsay RS, McDermott MM, Devereux RB, Jones KL, Fabsitz RR, et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality. Circulation 2004; 109: 733–739.
27. Xie J, Wu EQ, Zheng ZJ, Sullivan PW, Zhan L, Labarthe DR. Patient-reported health status in coronary heart disease in the United States. Circulation 2008; 118: 491–497.
28. Letterstal A, Forsberg C, Olofsson P, Wahlberg E. Risk attitudes to treatment among patients with severe intermittent claudication. J Vasc Surg 2008; 47: 988–994.
29. Longworth L, Buxton MJ, Sculpher M, Smith DH. Estimating utility data from clinical indicators for patients with stable angina. Eur J Health Econ 2005; 6: 347–353.
30. Burstrom K, Johannesson M, Rehnberg C. Deteriorating health status in Stockholm 1998–2002: results from repeated population surveys using the EQ-5D. Qual Life Res 2007; 16: 1547–1553.
31. Pharmaceutical Specialities in Sweden, 2009, http://www.fass.se.
32. Johannesson M. On the estimation of cost-effectiveness ratios. Health Policy 1995; 31: 225–229.
33. National Institute for Clinical Excellence NICE. Guide to the Methods of Technology Appraisal, 2004, http://www.nice.org.uk consulted October 2009.
34. Hunyady L, Catt KJ. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol 2006; 20: 953–970.
35. Meurin P. The ASCOT trial: clarifying the role of ACE inhibition in the reduction of cardiovascular events in patients with hypertension. Am J Cardiovasc Drugs 2006; 6(5): 327–334.
36. Tran H, Anand SS. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. JAMA 2004; 292: 1867–1874.
37. Sethi A, Arora RR. Medical management and cardiovascular risk reduction in peripheral arterial disease. Exp Clin Cardiol 2008; 13: 113–119.
38. Berger K, Hessel F, Kreuzer J, Smala A, Diener HC. Clopidogrel versus aspirin in patients with atherothrombosis. Curr Med Res Opin 2008; 24: 267–274.
39. O'Keefe JH, Carter MD, Lavie CJ. Primary and secondary prevention of cardiovascular diseases. Mayo Clin Proc 2009; 84: 741–757.
40. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, et al. AHA Guidelines for primary prevention of cardiovascular disease and stroke: 2002. Circulation 2002; 106: 388–391.
41. Neyt M, De Laet C, Van Brabandt H, Franco O, Ramaekers D. Cost-effectiveness of statins in the primary prevention of cardiovascular disease. Acta Cardiol 2009; 64: 1–10.
42. Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med 2006; 144: 326–336.
43. Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007; 11: 1–160, iii–iv.
44. Pilote L, Ho V, Lavoie F, Coupal L, Zowall H, Grover SA. Cost-effectiveness of lipid-lowering treatment according to lipid level. Can J Cardiol 2005; 21: 681–687.
45. Lamy A, Yusuf S, Pogue J, Gafni A. Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation 2003; 107: 960–965.
46. Rosen M. Monitoring public health and societal conditions in Sweden 1999–2003. The National Board of Health and Welfare, Centre for Epidemiology. Report; art. No. 2003-118-16, www.Sos.se/Sosmenye.htm.